Product
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2023-06-30